Bladder-Preserving Therapy Patterns of Care: A Survey of US Radiation Oncologists

Abhishek A. Solanki, Brendan Martin, Mark Korpics, Christina Small, Matthew M. Harkenrider, Timur Mitin

Research output: Contribution to journalArticle

  • 3 Citations

Abstract

Purpose Clinical trials have demonstrated the efficacy of bladder-preserving chemoradiation therapy (BPT) in muscle-invasive bladder cancer but have differed in the radiation therapy dose/fractionations, radiation therapy targets, and concurrent chemotherapy regimens used. No data exist on the technical and practical approaches actually used in clinical practice throughout the United States when delivering BPT. We performed a survey to explore radiation oncologists' practice patterns. Methods and Materials We conducted an electronic survey of US radiation oncologists regarding the management of patients with cT2-3N0M0 transitional cell muscle-invasive bladder cancer. The instrument included questions regarding the types of patients treated with BPT, as well as several aspects of treatment delivery. Descriptive statistics were reported for all responses. Pearson χ2 tests were used for univariate analysis. Results In total, 277 physicians completed our survey. Most respondents (58%) stated that they only treated 1 to 3 patients in the prior year. Seventy-four percent of respondents primarily treated patients deemed unfit for cystectomy, while only 28% saw patients prior to cystectomy for consultation to discuss BPT. The majority of radiation oncologists used conventional fractionation (91%) instead of hypofractionation (7.6%), but more variability existed for radiation therapy targets. Sixty percent used a small pelvis field, 29% used a whole-pelvis field, and 12% treated the bladder only. There was increased use of hypofractionation (29%) and bladder-only radiation therapy (34%) in patients who were not candidates for cystectomy or chemotherapy (P<.001). Cisplatin-based concurrent chemotherapy was most commonly preferred (89%). In non-cisplatin candidates, most respondents preferred 5-fluorouracil plus mitomycin C (32%) or carboplatin (32%). Intensity modulated radiation therapy use and midtreatment cystoscopic re-evaluation were variable, while hyperfractionation use was low. Conclusions Our study describes radiation oncologists' practice patterns for patients undergoing BPT. Although there are areas of consistency, variability exists in many technical and practical aspects of treatment delivery. Further research and education are needed to determine the optimal radiation therapy target, dose/fractionation, and concurrent chemotherapy regimen.

LanguageEnglish (US)
Pages383-387
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume99
Issue number2
DOIs
StatePublished - Oct 1 2017

Fingerprint

bladder
preserving
therapy
Urinary Bladder
Radiotherapy
radiation therapy
radiation
Cystectomy
chemotherapy
Dose Fractionation
Drug Therapy
fractionation
Pelvis
pelvis
Urinary Bladder Neoplasms
Therapeutics
delivery
cancer
Carboplatin
Mitomycin

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Bladder-Preserving Therapy Patterns of Care : A Survey of US Radiation Oncologists. / Solanki, Abhishek A.; Martin, Brendan; Korpics, Mark; Small, Christina; Harkenrider, Matthew M.; Mitin, Timur.

In: International Journal of Radiation Oncology Biology Physics, Vol. 99, No. 2, 01.10.2017, p. 383-387.

Research output: Contribution to journalArticle

Solanki, Abhishek A. ; Martin, Brendan ; Korpics, Mark ; Small, Christina ; Harkenrider, Matthew M. ; Mitin, Timur. / Bladder-Preserving Therapy Patterns of Care : A Survey of US Radiation Oncologists. In: International Journal of Radiation Oncology Biology Physics. 2017 ; Vol. 99, No. 2. pp. 383-387
@article{686bcc0308604c7599e53c67cccc1729,
title = "Bladder-Preserving Therapy Patterns of Care: A Survey of US Radiation Oncologists",
abstract = "Purpose Clinical trials have demonstrated the efficacy of bladder-preserving chemoradiation therapy (BPT) in muscle-invasive bladder cancer but have differed in the radiation therapy dose/fractionations, radiation therapy targets, and concurrent chemotherapy regimens used. No data exist on the technical and practical approaches actually used in clinical practice throughout the United States when delivering BPT. We performed a survey to explore radiation oncologists' practice patterns. Methods and Materials We conducted an electronic survey of US radiation oncologists regarding the management of patients with cT2-3N0M0 transitional cell muscle-invasive bladder cancer. The instrument included questions regarding the types of patients treated with BPT, as well as several aspects of treatment delivery. Descriptive statistics were reported for all responses. Pearson χ2 tests were used for univariate analysis. Results In total, 277 physicians completed our survey. Most respondents (58{\%}) stated that they only treated 1 to 3 patients in the prior year. Seventy-four percent of respondents primarily treated patients deemed unfit for cystectomy, while only 28{\%} saw patients prior to cystectomy for consultation to discuss BPT. The majority of radiation oncologists used conventional fractionation (91{\%}) instead of hypofractionation (7.6{\%}), but more variability existed for radiation therapy targets. Sixty percent used a small pelvis field, 29{\%} used a whole-pelvis field, and 12{\%} treated the bladder only. There was increased use of hypofractionation (29{\%}) and bladder-only radiation therapy (34{\%}) in patients who were not candidates for cystectomy or chemotherapy (P<.001). Cisplatin-based concurrent chemotherapy was most commonly preferred (89{\%}). In non-cisplatin candidates, most respondents preferred 5-fluorouracil plus mitomycin C (32{\%}) or carboplatin (32{\%}). Intensity modulated radiation therapy use and midtreatment cystoscopic re-evaluation were variable, while hyperfractionation use was low. Conclusions Our study describes radiation oncologists' practice patterns for patients undergoing BPT. Although there are areas of consistency, variability exists in many technical and practical aspects of treatment delivery. Further research and education are needed to determine the optimal radiation therapy target, dose/fractionation, and concurrent chemotherapy regimen.",
author = "Solanki, {Abhishek A.} and Brendan Martin and Mark Korpics and Christina Small and Harkenrider, {Matthew M.} and Timur Mitin",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.ijrobp.2017.04.009",
language = "English (US)",
volume = "99",
pages = "383--387",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Bladder-Preserving Therapy Patterns of Care

T2 - International Journal of Radiation Oncology Biology Physics

AU - Solanki,Abhishek A.

AU - Martin,Brendan

AU - Korpics,Mark

AU - Small,Christina

AU - Harkenrider,Matthew M.

AU - Mitin,Timur

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Purpose Clinical trials have demonstrated the efficacy of bladder-preserving chemoradiation therapy (BPT) in muscle-invasive bladder cancer but have differed in the radiation therapy dose/fractionations, radiation therapy targets, and concurrent chemotherapy regimens used. No data exist on the technical and practical approaches actually used in clinical practice throughout the United States when delivering BPT. We performed a survey to explore radiation oncologists' practice patterns. Methods and Materials We conducted an electronic survey of US radiation oncologists regarding the management of patients with cT2-3N0M0 transitional cell muscle-invasive bladder cancer. The instrument included questions regarding the types of patients treated with BPT, as well as several aspects of treatment delivery. Descriptive statistics were reported for all responses. Pearson χ2 tests were used for univariate analysis. Results In total, 277 physicians completed our survey. Most respondents (58%) stated that they only treated 1 to 3 patients in the prior year. Seventy-four percent of respondents primarily treated patients deemed unfit for cystectomy, while only 28% saw patients prior to cystectomy for consultation to discuss BPT. The majority of radiation oncologists used conventional fractionation (91%) instead of hypofractionation (7.6%), but more variability existed for radiation therapy targets. Sixty percent used a small pelvis field, 29% used a whole-pelvis field, and 12% treated the bladder only. There was increased use of hypofractionation (29%) and bladder-only radiation therapy (34%) in patients who were not candidates for cystectomy or chemotherapy (P<.001). Cisplatin-based concurrent chemotherapy was most commonly preferred (89%). In non-cisplatin candidates, most respondents preferred 5-fluorouracil plus mitomycin C (32%) or carboplatin (32%). Intensity modulated radiation therapy use and midtreatment cystoscopic re-evaluation were variable, while hyperfractionation use was low. Conclusions Our study describes radiation oncologists' practice patterns for patients undergoing BPT. Although there are areas of consistency, variability exists in many technical and practical aspects of treatment delivery. Further research and education are needed to determine the optimal radiation therapy target, dose/fractionation, and concurrent chemotherapy regimen.

AB - Purpose Clinical trials have demonstrated the efficacy of bladder-preserving chemoradiation therapy (BPT) in muscle-invasive bladder cancer but have differed in the radiation therapy dose/fractionations, radiation therapy targets, and concurrent chemotherapy regimens used. No data exist on the technical and practical approaches actually used in clinical practice throughout the United States when delivering BPT. We performed a survey to explore radiation oncologists' practice patterns. Methods and Materials We conducted an electronic survey of US radiation oncologists regarding the management of patients with cT2-3N0M0 transitional cell muscle-invasive bladder cancer. The instrument included questions regarding the types of patients treated with BPT, as well as several aspects of treatment delivery. Descriptive statistics were reported for all responses. Pearson χ2 tests were used for univariate analysis. Results In total, 277 physicians completed our survey. Most respondents (58%) stated that they only treated 1 to 3 patients in the prior year. Seventy-four percent of respondents primarily treated patients deemed unfit for cystectomy, while only 28% saw patients prior to cystectomy for consultation to discuss BPT. The majority of radiation oncologists used conventional fractionation (91%) instead of hypofractionation (7.6%), but more variability existed for radiation therapy targets. Sixty percent used a small pelvis field, 29% used a whole-pelvis field, and 12% treated the bladder only. There was increased use of hypofractionation (29%) and bladder-only radiation therapy (34%) in patients who were not candidates for cystectomy or chemotherapy (P<.001). Cisplatin-based concurrent chemotherapy was most commonly preferred (89%). In non-cisplatin candidates, most respondents preferred 5-fluorouracil plus mitomycin C (32%) or carboplatin (32%). Intensity modulated radiation therapy use and midtreatment cystoscopic re-evaluation were variable, while hyperfractionation use was low. Conclusions Our study describes radiation oncologists' practice patterns for patients undergoing BPT. Although there are areas of consistency, variability exists in many technical and practical aspects of treatment delivery. Further research and education are needed to determine the optimal radiation therapy target, dose/fractionation, and concurrent chemotherapy regimen.

UR - http://www.scopus.com/inward/record.url?scp=85028703019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028703019&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2017.04.009

DO - 10.1016/j.ijrobp.2017.04.009

M3 - Article

VL - 99

SP - 383

EP - 387

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -